Clinical Trials 2022: National Tribute and Awards



The ACTA Trial of the Year Awards were established in 2016 to honour and celebrate the outstanding Australian achievements that advance clinical practice and save or improve the lives of patients every year through collaborative, multicentre, investigator-driven clinical trials.

At a time when the spotlight is firmly on clinical trials across the globe, ACTA is incredibly proud to host these annual awards that honour the remarkable Australians who advance our health system by designing, conducting, or participating in ground-breaking clinical trials and promote the importance of clinical trials and the expertise and complexity of the work involved. We gratefully acknowledge the critical roles trialists, trial teams, consumers and industry partners have in delivering clinical trials and are proud to recognise these contributions.

In 2022, there are 4 award categories:

  1. ACTA Trial of the Year Award
  2. ACTA STInG Excellence in Trial Statistics Award
  3. ACTA Consumer Involvement Award
  4. ACTA Industry Partnership Award (New in 2022! Details below)


  • ACTA Trial of the Year Award - Trials considered for the ACTA Trial of the Year Award will be collaboratively developed, multicentre, investigator-driven, randomised controlled trials that were designed to improve patient-centred outcomes or healthcare delivery.
  • ACTA STInG Excellence in Trial Statistics Award - Alongside the judging process for ACTA Trial of the Year, nominated trials can be reviewed by an expert panel of statisticians convened by the ACTA Statistics in Trials Interest Group (ACTA STInG) for the ACTA STInG Excellence in Trial Statistics Award. This panel will consider the statistical methods summary provided within the trial nomination form, along with the trial’s published statistical analysis plan and primary results paper.
  • ACTA Consumer Involvement Award - Applicants should demonstrate exceptional creative and collaborative initiatives that involved consumers, incorporating the needs and values of patients and the public into trial protocol development (including priority setting) and design. Non-finalised/in-progress trials are eligible for this award providing recruitment for the trial is complete (as per the enrolment target) at the time of nomination.

- The trials nominated for these three awards must have been designed and led by a network or investigator group that is a current Member of ACTA (Full or Associate Member).
- If you are applying for the ACTA Trial of the Year Award/ACTA STInG Excellence in Trial Statistics Award - the primary results of the trial must have been published in the 2021 calendar year (electronically or in print).
- Please note that non-finalised/in-progress trials are eligible for the Consumer Involvement Award providing recruitment for the trial is complete (as per the enrolment target) at the time of nomination.

Nominations closed at midnight, Sunday 6 March 2022

ACTA Industry Partnership Award

With input from industry and sector colleagues, ACTA is proud to introduce the ACTA Industry Partnership Award in 2022. This award will be awarded to a collaboration between a commercial entity and a team of academic investigators that have combined to conduct a high-impact clinical trial. The term commercial entity includes pharmaceutical, biotechnology, medical technologies, digital medicine companies, and medical device manufacturers. 

Nominations for this award are open to ACTA members AND non members.

Assessment of the applications will be around the nature of the partnership; however, award judges will also be asked to confirm that the research undertaken in the trial in question was outstanding quality.

Award Eligibility criteria include:

  • Primary results of the nominated trial should be published in the 2021 calendar year (electronically or in print)
  • The academic investigators must be based in Australia
  • Nominees must have played a role in the collaborative clinical trial activity, and all joint parties must be disclosed on the application
  • Nominees will provide a description of how the trial and the involvement of the collaborating companies was vital in addressing a public health question
  • The nomination will be signed by an industry and academic representative involved in the trial
Nominations closed at midnight, Sunday 6 March 2022


Registrations are now open for the 2022 ACTA National Tribute and Awards Ceremony.

We know that our community see this event as a real highlight on the clinical trials sector calendar and we are delighted to share that Prof Anne Kelso AO has agreed to join us on the evening, speak on behalf of the NHMRC and present awards to our winners.

When: 5-7.15pm on Friday 20 May 2022, coinciding with International Clinical Trials Day.

Where: University of Sydney Business School

Cost: This is a free event, but please register for catering purposes.

We look forward to coming together in person to hear the announcements of our ACTA 2022 Trial of the Year Awards winners, as well as celebrating the ongoing work and achievements of all individuals and teams within the wider ACTA community during a networking reception.  We hope to see you there.


We sincerely thank Bellberry Limited and MTPConnect for joining us as a Premium Partners once again for this event.  

We also thank our longstanding In-Kind Supporters:

Please contact us if you need further information about the awards or the award ceremony.

Latest Resources

Latest Events